Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017
WALTHAM, Mass. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 London
View HTML
Toggle Summary Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
WALTHAM, Mass. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter
View HTML
Toggle Summary Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy
WALTHAM, Mass. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Dr.
View HTML
Toggle Summary Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017
Management to host conference call WALTHAM, Mass. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
Toggle Summary Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
WALTHAM, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Dr. Jay B.
View HTML
Toggle Summary Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
WALTHAM, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in a Phase 2b
View HTML
Toggle Summary Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
Proceeds from amended agreement, combined with finances raised from recent public stock offering and current financial resources, significantly extend Minerva cash runway Combined proceeds are expected to support anticipated data readouts from five planned clinical trials with three product
View HTML
Toggle Summary Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half of 2017 Amended agreement with Janssen supports dual focus of clinical development with MIN-202 in
View HTML
Toggle Summary American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass. , July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the American Journal of Psychiatry has published online
View HTML
Toggle Summary Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
WALTHAM, Mass. , July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business
View HTML